|
|
by Gray, Casey, Argáez, Charlene
Published 2019
Published 2019
Canadian Agency for Drugs and Technologies in Health
|
|
by Gray, Casey, Argáez, Charlene
Published 2019
Published 2019
Canadian Agency for Drugs and Technologies in Health
|
|
by Gray, Casey, Dulong, Camille, Argáez, Charlene
Published 2019
Published 2019
Canadian Agency for Drugs and Technologies in Health
|
|
by Gray, Casey, Argáez, Charlene
Published 2018
Published 2018
Canadian Agency for Drugs and Technologies in Health
|
|
by Gray, Casey, Argáez, Charlene
Published 2019
Published 2019
Canadian Agency for Drugs and Technologies in Health
|
|
by Gray, Casey, Grobelna, Aleksandra
Published 2019
Published 2019
Canadian Agency for Drugs and Technologies in Health
|
|
by Gray, Casey, Argáez, Charlene
Published 2018
Published 2018
Canadian Agency for Drugs and Technologies in Health
|
|
by Gray, Casey, Dulong, Camille, Argáez, Charlene
Published 2019
Published 2019
Canadian Agency for Drugs and Technologies in Health
|
|
by Gray, Casey, Argáez, Charlene
Published 2020
Published 2020
Canadian Agency for Drugs and Technologies in Health
|
|
by Gray, Casey, Grobelna, Aleksandra
Published 2019
Published 2019
Canadian Agency for Drugs and Technologies in Health
|
|
by Gray, Casey, McCormack, Suzanne
Published 2019
“... affects millions of Canadians. The prevalence of chronic pain not associated with cancer (also called non...”Published 2019
Canadian Agency for Drugs and Technologies in Health
|
|
by Gray, Casey, Argáez, Charlene
Published 2019
Published 2019
Canadian Agency for Drugs and Technologies in Health
|
|
by Gray, Casey, McCormack, Suzanne
Published 2019
“... affects millions of Canadians. The prevalence of chronic pain not associated with cancer (also called non...”Published 2019
Canadian Agency for Drugs and Technologies in Health
- 1
- 2